JY
RAPP

Jeff Yass’s Rapport Therapeutics RAPP Stock Holding History

Jeff Yass’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
8,255
-7,417
-47% -$273K ﹤0.01% 10753
2026
Q1 		$490K Buy
15,672
+5,464
+54% +$154K ﹤0.01% 9716
2025
Q4 		$310K Sell
10,208
-10,935
-52% -$303K ﹤0.01% 9870
2025
Q3 		$628K Sell
21,143
-3,741
-15% -$66.7K ﹤0.01% 8448
2025
Q2 		$283K Buy
24,884
+413
+2% +$4.38K ﹤0.01% 10484
2025
Q1 		$245K Buy
+24,471
New +$318K ﹤0.01% 10507

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jeff Yass's RAPP Position: Q2 2026 in Review

Jeff Yass reduced its Rapport Therapeutics (RAPP) stake by 47% in Q2 2026, selling an estimated $273K and leaving 8,255 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #10753.

Jeff Yass first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. The position peaked at $628K in Q3 2025. 159 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Jeff Yass held 8,255 shares of Rapport Therapeutics worth $344K as of Q2 2026.
  • Jeff Yass sold 7,417 Rapport Therapeutics shares in Q2 2026, an estimated $273K.
  • Rapport Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10753 holding.
  • Jeff Yass first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Jeff Yass's Rapport Therapeutics position peaked at $628K in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.